
Casein Kinase inhibitor A86
CAS No. 2079069-01-3
Casein Kinase inhibitor A86 ( CKIα inhibitor A86 )
产品货号. M13234 CAS No. 2079069-01-3
酪蛋白激酶抑制剂 A86(CKIα 抑制剂 A86)是一种新型泛特异性 CKI(CSNK1)抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
25MG | ¥9072 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Casein Kinase inhibitor A86
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述酪蛋白激酶抑制剂 A86(CKIα 抑制剂 A86)是一种新型泛特异性 CKI(CSNK1)抑制剂。
-
产品描述Casein Kinase inhibitor A86 (CKIα inhibitor A86) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=1-10 nM, CKIα Kd=9.8 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19; target both CDK7 and CDK9 with low nM Kd values; induces leukemia cell apoptosis at <160 nM, in correlation to the capacity to stabilize p53; shows high and selective sensitivity against leukemic CFUs in colony-forming unit (CFU) assay, without effect on normal hematopoietic CFUs; blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, induce apoptosis, abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1; demonstrates therapeutic efficacy with preserved hematopoiesis and leukemia cure potential in AML mouse models.
-
体外实验Casein Kinase inhibitor A86 is highly effective in inducing leukemia cell apoptosis at 160 nM or lower, mostly in correlation to their capacity to stabilize p53.Casein Kinase inhibitor A86 (0.08-2 μM; 6.5 hours) abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1. Casein Kinase inhibitor A86 induces a marked reduction in mRNA expression of MYC and MDM2, yet upregulates the expression of the Wnt targets AXIN2 and CCND1 (Cyclin D1).Cell Viability AssayCell Line:MV4-11 cells.Concentration:0.08 μM, 0.6 μM, 2 μM Incubation Time:6.5 hours Result:Abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1.
-
体内实验Pharmacokinetic studies of the inhibitor Casein Kinase inhibitor A86 at 20 mg/kg reveal rapid oral absorption with a Tmax of 0.2-0.5 hr, Cmax of 1115 ng/mL, T1/2 of 4.3 hr, and area under the curve (AUC) values of 2606 (ng*hr/mL).
-
同义词CKIα inhibitor A86
-
通路Metabolic Enzyme/Protease
-
靶点Casein Kinase
-
受体Casein Kinase
-
研究领域——
-
适应症——
化学信息
-
CAS Number2079069-01-3
-
分子量344.438
-
分子式C18H25FN6
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 12.5 mg/mL (36.29 mM)
-
SMILESCN1C(=C(C=N1)C2=NC(=NC=C2F)NC3CCC(CC3)N)CC4CC4
-
化学全称(1r,4r)-N1-(4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)cyclohexane-1,4-diamine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Minzel W, et al. Cell. 2018 Aug 20. pii: S0092-8674(18)30973-5. doi: 10.1016/j.cell.2018.07.045.